Why Novanta’s latest analyst upgrade matters now

Novanta (NOVT) has just been upgraded to a Zacks Rank #2, a move tied to higher earnings estimates that has pushed the stock back into focus for investors watching its fundamentals.

This renewed attention comes alongside a recently filed US$337.6 million shelf registration for 2,142,857 common shares, a routine financing tool that sits in the background while the earnings outlook takes center stage.

Novanta’s share price has climbed 33.56% over the past 90 days and the year to date share price return of 41.93% contrasts with a more modest 22.35% 1 year total shareholder return. This suggests recent momentum has picked up as the earnings upgrade draws attention to the stock, while the new shelf registration remains in the background.

If this earnings story has you looking beyond a single stock, it could be a good moment to see what else is moving in robotics and automation through the 29 robotics and automation stocks

With Novanta’s shares already up strongly in recent months and trading about 11% below the average analyst price target of US$175, the key question now is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 9.9% Undervalued

Novanta’s most followed valuation narrative pegs fair value at $175, a premium to the last close at $157.75, putting its long term earnings story in focus.

Rapid adoption of robotics and automation in manufacturing and healthcare (including AI-enabled warehouse automation, surgical robotics, and future humanoid robotics) is accelerating demand for Novanta's advanced sensing and precision motion technologies. The company's design wins and multi-year contracts (e.g., $50M warehouse robotics deal, multiple new design wins in physical AI and robotics) position it to grow revenue at above-market rates through 2026 and beyond.

Curious what sits behind that price target for Novanta? The narrative leans on ambitious earnings growth, expanding margins and a rich future profit multiple. The exact mix of assumptions might surprise you.

Result: Fair Value of $175 (UNDERVALUED)

However, the bullish Novanta story also depends on continued acquisition execution and resilient China related demand, both of which could disappoint and challenge today’s narrative.

Another view on Novanta’s valuation

So far the focus has been on future earnings power and fair value around $175 for Novanta, but the current P/E of 104.6x tells a very different story. That is above the US Electronic industry at 31.2x, the peer average at 56x, and even the fair ratio of 49.7x, which points to meaningful valuation risk if sentiment cools.

Our DCF model also flags a gap, with Novanta at $157.75 compared with a future cash flow value of $104.71, which screens as overvalued rather than undervalued. With multiples and the SWS DCF model both flashing caution, how comfortable are you with paying up for this earnings narrative?

Next Steps

With sentiment on Novanta clearly mixed, the real edge comes from seeing the full picture for yourself and deciding quickly where you stand, starting with the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Novanta?

If Novanta has sharpened your focus, do not stop here. Broader ideas from the Simply Wall Street Screener could reveal opportunities you will wish you checked sooner.

• Spot potential bargains early by scanning the 42 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect their underlying businesses.
• Strengthen your income playbook by reviewing the 9 dividend fortresses that concentrate on higher yielding companies with resilient payout profiles.
• Prioritize resilience by checking the 72 resilient stocks with low risk scores that emphasize companies with steadier risk profiles to complement more aggressive positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.